Clinical trial
Open Multicenter Controlled Clinical Trial to Evaluate Safety and Efficacy of Aerosolized MIR 19 ® Inhalation in Patients With Moderate COVID-19 Who Did Not Require Treatment in the Intensive Care Unit.
NCT05184127 is registered in ClinicalTrials.gov with National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Open Multicenter Controlled Clinical Trial to Evaluate Safety and Efficacy of Aerosolized MIR 19 ® Inhalation in Patients With Moderate COVID-19 Who Did Not Require Treatment in the Intensive Care Unit.
- Lead sponsor
- National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 27, 2021
- Completion date
- September 7, 2021
- Enrollment
- 156 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.